13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
137 檔
33.0%
During the Q3 2024 filing period, Blue Owl Capital Holdings LP (CIK: 0001858703) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $664.5M across 137 reported positions.
In Q3 2024, Blue Owl Capital Holdings LP displayed an active expansion posture, initiating 19 new positions and adding to 9 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 13.57% | -3.32% | — | |
| 2 | KVYO | Klaviyo Inc-a | Stock-Other | 8.18% | — | — | |
| 3 | TRML | Tourmaline Bio Inc | Stock-Other | 7.59% | — | -10.78% | |
| 4 | PLRX | Pliant Therapeutics Inc | Stock-Other | 6.50% | -1.01% | EXIT | |
| 5 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 6.49% | -3.07% | -1.86% | |
| 6 | OBDC | Blue Owl Capital CORP | Stock-Financials | 5.75% | -2.73% | — | |
| 7 | LRMR | Larimar Therapeutics Inc | Stock-Other | 5.26% | -4.40% | +7.96% | |
| 8 | TQQQ | Proshares Ultrapro Qqq | ETF-Other | 4.54% | — | — | |
| 9 | ✓ | Engene Holdings Inc | Stock-Other | 3.89% | -8.08% | EXIT | |
| 10 | EVCM | Evercommerce Inc | Stock-Other | 3.28% | — | — | |
| 11 | ✓ | Acelyrin Inc | Stock-Other | 2.66% | — | -4.51% | |
| 12 | CNDT | Conduent Inc | Stock-Other | 2.61% | -0.62% | — | |
| 13 | RPTX | Repare Therapeutics Inc | Stock-Other | 2.24% | — | — | |
| 14 | CNTX | Context Therapeutics Inc | Stock-Other | 2.05% | -3.34% | +4.84% | |
| 15 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.75% | -0.78% | -39.14% | |
| 16 | IRON | Disc Medicine Inc | Stock-Other | 1.66% | — | -18.58% | |
| 17 | HLLY | Holley Inc | Stock-Other | 1.45% | -1.81% | — | |
| 18 | ETWOGBP | E2open Parent Holdings Inc | Stock-Other | 1.40% | — | — | |
| 19 | KROS | Keros Therapeutics Inc | Stock-Other | 1.37% | — | -22.20% | |
| 20 | ✓ | Ikena Oncology Inc | Stock-Other | 1.37% | — | — | |
| 21 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.18% | -0.91% | +7.46% | |
| 22 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.13% | — | — | |
| 23 | ✓ | Lanzatech Global Inc | Stock-Other | 1.08% | — | — | |
| 24 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.02% | -2.99% | +1.77% | |
| 25 | CCC | Ccc Intelligent Solutions Ho | Stock-Tech | 0.97% | — | — | |
| 26 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 0.89% | +1.00% | — | |
| 27 | STWD | Starwood Property Trust Inc | Stock-Real Estate | 0.89% | -0.25% | — | |
| 28 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.80% | — | +7.65% | |
| 29 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.79% | — | — | |
| 30 | JANX | Janux Therapeutics Inc | Stock-Other | 0.70% | — | +100.00% | |
| 31 | ✓ | Stock-Other | 0.68% | — | — | ||
| 32 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.67% | — | -5.57% | |
| 33 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.55% | — | +18.18% | |
| 34 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.50% | — | -56.84% | |
| 35 | BRZE | Braze Inc-a | Stock-Other | 0.49% | — | — | |
| 36 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.46% | — | -56.45% | |
| 37 | ✓ | Adc Therapeutics SA | Stock-Other | 0.45% | -0.58% | — | |
| 38 | IMVT | Immunovant Inc | Stock-Other | 0.44% | — | — | |
| 39 | BLND | Blend Labs Inc-a | Stock-Other | 0.26% | — | — | |
| 40 | PAYO | Payoneer Global Inc | Stock-Other | 0.26% | — | — | |
| 41 | OHI | Omega Healthcare Investors, Inc. | Stock-Real Estate | 0.25% | — | — | |
| 42 | NU | Nu Holdings Ltd. | Stock-Financials | 0.24% | — | — | |
| 43 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.21% | — | +51.34% | |
| 44 | EPD | Enterprise Products Partners | Stock-Energy | 0.18% | -0.32% | EXIT | |
| 45 | ✓ | Stock-Other | 0.16% | — | — | ||
| 46 | GOCOQ | Gohealth Inc-class A | Stock-Other | 0.15% | -0.02% | EXIT | |
| 47 | TQQQ | ProShares UltraPro QQQ | ETF-Other | 0.14% | — | — | |
| 48 | ✓ | Engene Holdings Inc | Stock-Other | 0.14% | -0.35% | EXIT | |
| 49 | ✓ | Marblegate Acquisition Corp | Stock-Other | 0.13% | — | — | |
| 50 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.09% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | +13.6% | NEW | New buy |
| 2 | TQQQ | Proshares Ultrapro Qqq | +4.5% | NEW | New buy |
| 3 | CNDT | Conduent Inc | +2.6% | NEW | New buy |
| 4 | TRML | Tourmaline Bio Inc | +1.5% | -10.78% | Trim |
| 5 | HLLY | Holley Inc | +1.5% | NEW | New buy |
| 6 | ✓ | Lanzatech Global Inc | +1.1% | NEW | New buy |
| 7 | CCC | Ccc Intelligent Solutions Ho | +1% | NEW | New buy |
| 8 | 260 | Centessa Pharmaceuticals-adr | +0.8% | NEW | New buy |
| 9 | ✓ | +0.7% | NEW | New buy | |
| 10 | BRZE | Braze Inc-a | +0.5% | NEW | New buy |
| 11 | AQST | Aquestive Therapeutics Inc | +0.4% | +7.46% | Add |
| 12 | PAYO | Payoneer Global Inc | +0.3% | NEW | New buy |
| 13 | NU | Nu Holdings Ltd. | +0.2% | NEW | New buy |
| 14 | CMPX | Compass Therapeutics Inc | +0.2% | +1.77% | Add |
| 15 | JANX | Janux Therapeutics Inc | +0.2% | +100.00% | Add |
| 16 | EPD | Enterprise Products Partners | +0.2% | NEW | New buy |
| 17 | ✓ | +0.2% | NEW | New buy | |
| 18 | TQQQ | ProShares UltraPro QQQ | +0.1% | NEW | New buy |
| 19 | ✓ | Marblegate Acquisition Corp | +0.1% | NEW | New buy |
| 20 | ROIV | Roivant Sciences Ltd. | +0.1% | NEW | New buy |
| 21 | SLND-WS | Legato Merger CORP Ii -cw23 | +0.1% | NEW | New buy |
| 22 | CAH | Cardinal Health Inc | 0% | NEW | New buy |
| 23 | 62C | Piper Sandler Cos | 0% | NEW | New buy |
| 24 | BLND | Blend Labs Inc-a | 0% | — | Unchanged |
| 25 | GPCR | Structure Therapeutics Inc | -0.1% | +18.18% | Add |
| 26 | PLMKW | Plum Acquisition Corp. IV | -0.1% | -78.57% | Trim |
| 27 | KVYO | Klaviyo Inc-a | -0.1% | — | Unchanged |
| 28 | PYXS | Pyxis Oncology Inc | -0.2% | +7.65% | Add |
| 29 | MREO | Mereo Biopharma Group Pl-adr | -0.2% | -5.57% | Trim |
| 30 | ✓ | Inozyme Pharma Inc | -0.3% | — | Unchanged |
| 31 | SYRS | Syros Pharmaceuticals Inc | -0.3% | +51.34% | Add |
| 32 | CELC | Celcuity Inc | -0.3% | EXIT | Sold out |
| 33 | STWD | Starwood Property Trust Inc | -0.3% | — | Unchanged |
| 34 | OHI | Omega Healthcare Investors, Inc. | -0.4% | — | Unchanged |
| 35 | ✓ | Ikena Oncology Inc | -0.5% | — | Unchanged |
| 36 | SGMT | Sagimet Biosciences Inc-a | -0.7% | — | Unchanged |
| 37 | CNTX | Context Therapeutics Inc | -0.8% | +4.84% | Add |
| 38 | RPTX | Repare Therapeutics Inc | -0.9% | — | Unchanged |
| 39 | VKTX | Viking Therapeutics Inc | -0.9% | -56.84% | Trim |
| 40 | ✓ | Acelyrin Inc | -0.9% | -4.51% | Trim |
| 41 | MLYS | Mineralys Therapeutics Inc | -1% | -56.45% | Trim |
| 42 | IRON | Disc Medicine Inc | -1% | -18.58% | Trim |
| 43 | RARE | Ultragenyx Pharmaceutical In | -1.3% | -39.14% | Trim |
| 44 | EVCM | Evercommerce Inc | -1.7% | — | Unchanged |
| 45 | TOST | Toast Inc-class A | -2.3% | EXIT | Sold out |
| 46 | PLRX | Pliant Therapeutics Inc | -2.5% | — | Unchanged |
| 47 | LRMR | Larimar Therapeutics Inc | -2.5% | +7.96% | Add |
| 48 | ✓ | Engene Holdings Inc | -2.5% | +24.86% | Add |
| 49 | OBDC | Blue Owl Capital CORP | -3% | — | Unchanged |
| 50 | CGEM | Cullinan Therapeutics Inc | -3.5% | -1.86% | Trim |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 137 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NCDL, KVYO, TRML) accounted for 33.0% of total reported equity market value during Q3 2024.
Top New Position Initiated
NCDL
市值: $70.4M
Top Position Liquidated / Trimmed
TOST
前期市值: $8.3M
During Q3 2024, Blue Owl Capital Holdings LP's top holdings by market value included NCDL (13.6%)、KVYO (8.2%)、TRML (7.6%). The largest single position, NCDL, represented 13.6% of total portfolio value.
In Q3 2024, Blue Owl Capital Holdings LP made 39 total portfolio adjustments, initiating 19 new buys, adding to 9 positions, trimming 9 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.